Back to Search Start Over

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers:an international cohort study

Authors :
Schrijver, Lieske H.
Antoniou, Antonis C.
Olsson, Håkan
Mooij, Thea M.
Roos-Blom, Marie José
Azarang, Leyla
Adlard, Julian
Ahmed, Munaza
Barrowdale, Daniel
Davidson, Rosemarie
Donaldson, Alan
Eeles, Ros
Evans, D. Gareth
Frost, Debra
Henderson, Alex
Izatt, Louise
Ong, Kai Ren
Bonadona, Valérie
Coupier, Isabelle
Faivre, Laurence
Fricker, Jean Pierre
Gesta, Paul
van Engelen, Klaartje
Jager, Agnes
Menko, Fred H.
Mourits, Marian J.E.
Singer, Christian F.
Tan, Yen Y.
Foretova, Lenka
Navratilova, Marie
Schmutzler, Rita K.
Ellberg, Carolina
Engel, Christoph
Andrieu, N
Rookus, Matti A.
Schrijver, Lieske H.
Antoniou, Antonis C.
Olsson, Håkan
Mooij, Thea M.
Roos-Blom, Marie José
Azarang, Leyla
Adlard, Julian
Ahmed, Munaza
Barrowdale, Daniel
Davidson, Rosemarie
Donaldson, Alan
Eeles, Ros
Evans, D. Gareth
Frost, Debra
Henderson, Alex
Izatt, Louise
Ong, Kai Ren
Bonadona, Valérie
Coupier, Isabelle
Faivre, Laurence
Fricker, Jean Pierre
Gesta, Paul
van Engelen, Klaartje
Jager, Agnes
Menko, Fred H.
Mourits, Marian J.E.
Singer, Christian F.
Tan, Yen Y.
Foretova, Lenka
Navratilova, Marie
Schmutzler, Rita K.
Ellberg, Carolina
Engel, Christoph
Andrieu, N
Rookus, Matti A.
Source :
Schrijver , L H , Antoniou , A C , Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study , Olsson , H , Mooij , T M , Roos-Blom , M J , Azarang , L , Adlard , J , Ahmed , M , Barrowdale , D , Davidson , R , Donaldson , A , Eeles , R , Evans , D G , Frost , D , Henderson , A , Izatt , L , Ong , K R , Bonadona , V , Coupier , I , Faivre , L , Fricker , J P , Gesta , P , van Engelen , K , Jager , A , Menko , F H , Mourits , M J E , Singer , C F , Tan , Y Y , Foretova , L , Navratilova , M , Schmutzler , R K , Ellberg , C , Engel , C , Andrieu , N & Rookus , M A 2021 , ' Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study ' , American Journal of Obstetrics and Gynecology , vol. 225 , no. 1 , pp. 51.e1-51.e17 .
Publication Year :
2021

Abstract

Background: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in the general population are well established (approximately 50% risk reduction in ovarian cancer), the estimated risk reduction in mutation carriers is much less precise because of potential bias and small sample sizes. In addition, only a few studies on oral contraceptive use have examined the associations of duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer. Objective: This study aimed to investigate in more detail the associations of various characteristics of oral contraceptive use and risk of ovarian cancer, to provide healthcare providers and carriers with better risk estimates. Study Design: In this international retrospective study, ovarian cancer risk associations were assessed using oral contraceptives data on 3989 BRCA1 and 2445 BRCA2 mutation carriers. Age-dependent–weighted Cox regression analyses were stratified by study and birth cohort and included breast cancer diagnosis as a covariate. To minimize survival bias, analyses were left truncated at 5 years before baseline questionnaire. Separate analyses were conducted for each aspect of oral contraceptive use and in a multivariate analysis, including all these aspects. In addition, the analysis of duration of oral contraceptive use was stratified by recency of use. Results: Oral contraceptives were less often used by mutation carriers who were diagnosed with ovarian cancer (ever use: 58.6% for BRCA1 and 53.5% BRCA2) than by unaffected carriers (ever use: 88.9% for BRCA1 and 80.7% for BRCA2). The median duration of use was 7 years for both BRCA1 and BRCA2 carriers who developed ovarian cancer and 9 and 8 years for unaffected BRCA1 and BRCA2 carriers with ovarian cancer, respectively. For BRCA1 mutation carriers, univariate analyses have shown that both

Details

Database :
OAIster
Journal :
Schrijver , L H , Antoniou , A C , Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study , Olsson , H , Mooij , T M , Roos-Blom , M J , Azarang , L , Adlard , J , Ahmed , M , Barrowdale , D , Davidson , R , Donaldson , A , Eeles , R , Evans , D G , Frost , D , Henderson , A , Izatt , L , Ong , K R , Bonadona , V , Coupier , I , Faivre , L , Fricker , J P , Gesta , P , van Engelen , K , Jager , A , Menko , F H , Mourits , M J E , Singer , C F , Tan , Y Y , Foretova , L , Navratilova , M , Schmutzler , R K , Ellberg , C , Engel , C , Andrieu , N & Rookus , M A 2021 , ' Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study ' , American Journal of Obstetrics and Gynecology , vol. 225 , no. 1 , pp. 51.e1-51.e17 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1352447680
Document Type :
Electronic Resource